Evaheart Revenue and Competitors

Houston, TX USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Evaheart's estimated annual revenue is currently $2.6M per year.(i)
  • Evaheart's estimated revenue per employee is $155,000

Employee Data

  • Evaheart has 17 Employees.(i)
  • Evaheart grew their employee count by -6% last year.

Evaheart's People

NameTitleEmail/Phone
1
Clinical Support SpecialistReveal Email/Phone
2
Lead Clinical Support SpecialistReveal Email/Phone
3
Associate Clinical Trial LeadReveal Email/Phone
4
Clinical Support SpecialistReveal Email/Phone
5
Clinical Support SpecialistReveal Email/Phone
6
Clinical Support SpecialistReveal Email/Phone
7
Clinical Support SpecialistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.7M11-8%N/AN/A
#2
$14.9M96-6%N/AN/A
#3
$15.2M983%$1.8MN/A
#4
$1.6M100%N/AN/A
#5
$3.4M220%N/AN/A
#6
$2.8M1850%N/AN/A
#7
$7.4M48-2%N/AN/A
#8
$0.8M50%N/AN/A
#9
$1.6M100%N/AN/A
#10
$16.3M10562%N/AN/A
Add Company

What Is Evaheart?

LEADING LVAD COMPANY IN THE STATE OF TEXAS Evaheart, Inc. ("EVI") is a medical device company based in the Texas Medical Center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART®2 Left Ventricular Assist System in the North American market and start distribution in Europe. Under an FDA-approved IDE, a Multi-Center Prospective Randomized Clinical Trial (COMPETENCE TRIAL) of the EVAHEART®2 LVAS is currently ongoing in US. OUR MISSION To return severe heart failure patients to their home with high quality of life. WHAT WE'VE ACHIEVED - Over 9-year durability testing with no mechanical failure. - Regulatory clearance granted (by PMDA) and now clinically used in Japan - Total 183 EVAHEART® LVAS have been implanted to-date (July-2018). - IDE (Investigational Device Exemption) approved by the FDA. - IDE clinical trial (BTT trial) in North America is underway. - New miniaturized pump and inflow cannula are implemented. "RESPECT PULSATILITY" (c) Christian Schmidt-Mewes

keywords:N/A

N/A

Total Funding

17

Number of Employees

$2.6M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Evaheart News

2022-04-17 - Global Long-term Mechanical Circulatory Support (LT-MCS) Market ...

Abbott Laboratories; LivaNova; Nipro Corporation; Terumo Corporation; Medtronic; BiVACOR; Evaheart; Abiomed. DOWNLOAD FREE SAMPLE REPORT:...

2022-04-17 - Global Mechanical Circulatory Support (MCS) Market 2022 Future ...

CorWave; SynCardia Systems; BiVACOR; Evaheart; Abiomed; Procyrion; NuPulseCV; Windmill Cardiovascular Systems. The study examines the following...

2022-04-13 - Global LVAD Market 2022 Future Scenario – Abiomed, Berlin Heart ...

Evaheart; ReliantHeart; Sun Medical Technology Research; Sunshine Heart. Market segment by product type: BTT Therapy; BTD Therapy; Destination...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M17-11%N/A
#2
$2.5M17N/AN/A
#3
$2.8M17N/AN/A
#4
$1.5M17N/AN/A
#5
$1.5M17N/AN/A